Precision BioSciences wins CTA approval to expand ELIMINATE-B trial into France, Romania

Precision BioSciences

Precision BioSciences

DTIL

0.00
  • Precision BioSciences received Clinical Trial Application clearance to expand ELIMINATE-B trial of PBGENE-HBV into France and Romania.
  • Authorization enables site initiation activities, with initial patient screening expected in Q2 2026.
  • Move aims to broaden European enrollment for PBGENE-HBV, an in vivo gene-editing therapy targeting chronic hepatitis B.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604150701BIZWIRE_USPR_____20260415_BW450685) on April 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.